Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie’s latest clinical study, officially titled ‘A Phase 2, Randomized, Open-Label Study Comparing Telisotuzumab Adizutecan (ABBV-400) Monotherapy to the Current Standard of Care in Subjects With Post Adjuvant ctDNA Positive Colorectal Cancer and No Radiographic Evidence of Disease (NED),’ aims to evaluate the change in disease activity in colorectal cancer patients. This study is significant as colorectal cancer is the third most common cancer worldwide, and the study seeks to determine the efficacy of telisotuzumab adizutecan compared to standard treatments.
The study tests the investigational drug telisotuzumab adizutecan, administered intravenously, against the standard of care (SOC) treatment. The primary goal is to assess its effectiveness in treating colorectal cancer without radiographic evidence of disease.
This interventional study follows a non-randomized, parallel assignment model without masking, focusing on treatment as its primary purpose. It involves two groups: one receiving telisotuzumab adizutecan and the other receiving SOC, with a total of approximately 140 participants across 45 sites worldwide.
The study is set to begin on September 5, 2025, with an estimated duration of 51 months. The primary completion and overall study completion dates are yet to be determined, with the last update submitted on August 1, 2025.
For investors, this study could influence AbbVie’s stock performance as it progresses, especially if telisotuzumab adizutecan shows promising results. The outcome may also impact the competitive landscape in colorectal cancer treatment, potentially affecting market dynamics.
The study is currently recruiting, with further details available on the ClinicalTrials portal.